Trials / Completed
CompletedNCT02105454
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)
A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, participants with hepatitis C virus (HCV) genotype 1 (GT1) who failed prior direct-acting antiviral (DAA) therapy will receive Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) to evaluate sustained virologic response (SVR) using this drug combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Grazoprevir (GZR) | 100 mg oral tablet (total daily dose) |
| DRUG | Elbasvir (EBR) | 10 mg oral capsule (total daily dose = 5 capsules) |
| DRUG | Ribavirin (RBV) | 200 mg oral capsule (total daily dose = 4-7 capsules) |
Timeline
- Start date
- 2014-05-23
- Primary completion
- 2015-05-04
- Completion
- 2015-05-04
- First posted
- 2014-04-07
- Last updated
- 2018-09-24
- Results posted
- 2016-03-04
Source: ClinicalTrials.gov record NCT02105454. Inclusion in this directory is not an endorsement.